Marksans Pharma Limited (MARKSANS.BO)
INR 197.55
(-1.81%)
INR 197.55
(-1.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 7.79 Billion INR | 28.18% |
| 2022 | 2.99 Billion INR | 45.29% |
| 2021 | 2.06 Billion INR | -30.91% |
| 2020 | 2.98 Billion INR | 84.62% |
| 2019 | 1.61 Billion INR | 65.24% |
| 2018 | 979.08 Million INR | 120.81% |
| 2017 | 443.4 Million INR | 185.53% |
| 2016 | 155.29 Million INR | -85.47% |
| 2015 | 1.06 Billion INR | -31.46% |
| 2014 | 1.55 Billion INR | 80.4% |
| 2013 | 864.11 Million INR | 98.43% |
| 2012 | 435.47 Million INR | 124.88% |
| 2011 | -1.75 Billion INR | -91.13% |
| 2010 | -915.6 Million INR | -1002.54% |
| 2009 | 101.44 Million INR | -30.28% |
| 2008 | 145.51 Million INR | -55.08% |
| 2007 | 323.93 Million INR | 55.51% |
| 2006 | 208.3 Million INR | -33.67% |
| 2005 | 314.06 Million INR | 25.28% |
| 2004 | 250.67 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.07 Billion INR | 180.35% |
| 2023 Q4 | 885.87 Million INR | -23.51% |
| 2023 Q2 | 963.98 Million INR | 9.16% |
| 2023 Q3 | 1.15 Billion INR | 20.15% |
| 2023 FY | 3.84 Billion INR | 28.18% |
| 2023 Q1 | 883.06 Million INR | -7.63% |
| 2022 Q4 | 956.05 Million INR | 49.61% |
| 2022 Q3 | 639.02 Million INR | -3.49% |
| 2022 FY | 2.99 Billion INR | 45.29% |
| 2022 Q1 | 617.46 Million INR | 46.03% |
| 2022 Q2 | 662.15 Million INR | 7.24% |
| 2021 Q4 | 422.83 Million INR | -14.14% |
| 2021 Q2 | 527.11 Million INR | -24.55% |
| 2021 Q3 | 492.44 Million INR | -6.58% |
| 2021 FY | 2.06 Billion INR | -30.91% |
| 2021 Q1 | 698.66 Million INR | -25.71% |
| 2020 FY | 2.98 Billion INR | 84.62% |
| 2020 Q1 | 629.54 Million INR | 12.77% |
| 2020 Q2 | 678.32 Million INR | 7.75% |
| 2020 Q3 | 793.14 Million INR | 16.93% |
| 2020 Q4 | 940.4 Million INR | 18.57% |
| 2019 FY | 1.61 Billion INR | 65.24% |
| 2019 Q1 | 298.63 Million INR | 94.14% |
| 2019 Q2 | 364.72 Million INR | 22.13% |
| 2019 Q3 | 399.84 Million INR | 9.63% |
| 2019 Q4 | 558.24 Million INR | 39.62% |
| 2018 Q2 | 307.87 Million INR | -5.95% |
| 2018 Q4 | 153.82 Million INR | -50.87% |
| 2018 FY | 979.08 Million INR | 120.81% |
| 2018 Q1 | 327.34 Million INR | 652.19% |
| 2018 Q3 | 313.1 Million INR | 1.7% |
| 2017 Q2 | 145.74 Million INR | -25.86% |
| 2017 FY | 443.4 Million INR | 185.53% |
| 2017 Q4 | -59.28 Million INR | -127.9% |
| 2017 Q3 | 212.46 Million INR | 45.78% |
| 2017 Q1 | 196.57 Million INR | 1547.85% |
| 2016 Q1 | 73.81 Million INR | 1601.96% |
| 2016 FY | 155.29 Million INR | -85.47% |
| 2016 Q3 | 131.47 Million INR | 17174.03% |
| 2016 Q4 | -13.57 Million INR | -110.33% |
| 2016 Q2 | -770 Thousand INR | -101.04% |
| 2015 FY | 1.06 Billion INR | -31.46% |
| 2015 Q2 | 430.34 Million INR | -4.16% |
| 2015 Q1 | 449.02 Million INR | 23.67% |
| 2015 Q3 | 184.87 Million INR | -57.04% |
| 2015 Q4 | 4.33 Million INR | -97.65% |
| 2014 Q4 | 363.07 Million INR | -13.86% |
| 2014 Q2 | 422.08 Million INR | 19.84% |
| 2014 FY | 1.55 Billion INR | 80.4% |
| 2014 Q1 | 352.21 Million INR | 107.58% |
| 2014 Q3 | 421.49 Million INR | -0.14% |
| 2013 Q2 | 224.87 Million INR | 12.48% |
| 2013 FY | 864.11 Million INR | 98.43% |
| 2013 Q4 | 169.67 Million INR | -37.08% |
| 2013 Q3 | 269.65 Million INR | 19.91% |
| 2013 Q1 | 199.92 Million INR | -46.13% |
| 2012 Q3 | 87.01 Million INR | -40.39% |
| 2012 Q2 | 145.97 Million INR | 189.12% |
| 2012 FY | 435.47 Million INR | 124.88% |
| 2012 Q1 | -163.79 Million INR | 0.0% |
| 2012 Q4 | 371.08 Million INR | 326.45% |
| 2011 FY | -1.75 Billion INR | -91.13% |
| 2010 FY | -915.6 Million INR | -1002.54% |
| 2009 FY | 101.44 Million INR | -30.28% |
| 2008 FY | 145.51 Million INR | -55.08% |
| 2007 FY | 323.93 Million INR | 55.51% |
| 2006 FY | 208.3 Million INR | -33.67% |
| 2005 FY | 314.06 Million INR | 25.28% |
| 2004 FY | 250.67 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott India Limited | 13.79 Billion INR | 43.515% |
| Cipla Limited | 105.7 Billion INR | 92.629% |
| Gland Pharma Limited | 9.9 Billion INR | 21.355% |
| GlaxoSmithKline Pharmaceuticals Limited | 13.6 Billion INR | 42.717% |
| Kopran Limited | 615.26 Million INR | -1166.382% |
| NGL Fine-Chem Limited | 416.27 Million INR | -1771.759% |
| Pfizer Limited | 9.61 Billion INR | 18.936% |
| Sanofi India Limited | 7.79 Billion INR | 0.095% |
| SMS Pharmaceuticals Limited | 833.64 Million INR | -834.642% |